Kronos Bio Inc. (KRON): Price and Financial Metrics


Kronos Bio Inc. (KRON): $3.69

0.28 (+8.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KRON to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KRON Stock Price Chart Interactive Chart >

Price chart for KRON

KRON Price/Volume Stats

Current price $3.69 52-week high $28.42
Prev. close $3.41 52-week low $3.21
Day low $3.35 Volume 605,200
Day high $3.73 Avg. volume 372,018
50-day MA $5.57 Dividend yield N/A
200-day MA $12.35 Market Cap 209.34M

Kronos Bio Inc. (KRON) Company Bio


Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.


KRON Latest News Stream


Event/Time News Detail
Loading, please wait...

KRON Latest Social Stream


Loading social stream, please wait...

View Full KRON Social Stream

Latest KRON News From Around the Web

Below are the latest news stories about Kronos Bio Inc that investors may wish to consider to help them evaluate KRON as an investment opportunity.

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results

Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib trial to start in Q1 2022; Phase 3 registrational AGILITY trial of entospletinib underway, with results anticipated in the second half of 2023 $339.5 million in cash, cash equivalents and investments as of December 31, 2021, providing expected runway into the second half of 2024 SAN MATEO, Calif. and CA

Yahoo | February 24, 2022

Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development. Dr. Olek joins Kronos Bio from Loxo Oncology at Lilly. Dr. Olek will be responsible for the planning, conduct and analysis of Kronos Bio’s clinical trials, reporting to Jorge DiMa

Yahoo | February 1, 2022

We're Not Very Worried About Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 31, 2022

Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00

Kronos Bio, Inc. (NASDAQ:KRON) shares gapped down before the market opened on Tuesday . The stock had previously closed at $14.00, but opened at $13.70. Kronos Bio shares last traded at $14.66, with a volume of 1,131 shares trading hands. Several analysts recently commented on KRON shares. Zacks Investment Research raised Kronos Bio from a […] The post Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00 appeared first on ETF Daily News .

ETF Daily News | December 23, 2021

Kronos Bio, Inc. (NASDAQ:KRON) VP Sells $202,892.74 in Stock

Kronos Bio, Inc. (NASDAQ:KRON) VP Jorge Dimartino sold 16,402 shares of the firms stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $12.37, for a total value of $202,892.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through []

Transcript Daily | December 18, 2021

Read More 'KRON' Stories Here

KRON Price Returns

1-mo -25.45%
3-mo -50.60%
6-mo -68.13%
1-year -84.88%
3-year N/A
5-year N/A
YTD -72.85%
2021 -54.50%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4929 seconds.